Trials / Completed
CompletedNCT01586936
Non-Interventional Study of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With Inhibitors
Special Survey of Production of Antibody Against Coagulation
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 9 (actual)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This study is conducted in Japan. The aim of this registry study is to observe the use of single dose and multi-dose use of eptacog alpha (NovoSeven®) and to compare short-term outcomes, including effectiveness, safety, quality of life and treatment satisfaction with the approved treatments.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | eptacog alfa (activated) | Prescription of eptacog alpha at the discretion of the physician |
Timeline
- Start date
- 1999-03-10
- Primary completion
- 2010-03-09
- Completion
- 2010-03-09
- First posted
- 2012-04-27
- Last updated
- 2017-02-27
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT01586936. Inclusion in this directory is not an endorsement.